Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00238914 · ClinicalTrials.gov registry record · Phase 2

Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1

A Phase 2 study of Heroin Dependence, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT00238914: Completed Phase 2 study of Heroin Dependence, sponsored by New York State Psychiatric Institute.

NCT00238914 is a Phase 2 study of Heroin Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants, below the 108-participant average among 8 other Heroin Dependence trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00238914, a Phase 2 study of Heroin Dependence, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES: 1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of relapse to illicit opiates compared to naltrexone plus Compliance Enhancement (CE) Therapy. 2. Lifetime history of depression will predict dysphoria and non-compliance with naltrexone.

Conditions Studied

Interventions

  • DRUG Naltrexone
  • BEHAVIORAL Behavioral Naltrexone Therapy (BNT)
  • BEHAVIORAL Compliance Enhancement (CE)

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 1999-08
Est. Completion 2002-07
Phase Phase 2

What the finished NCT00238914 record still lists

NCT00238914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 108-participant average among 8 other Heroin Dependence trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Heroin Dependence appearing as the primary indexed condition, and to 3 interventions - of which Naltrexone is the first listed.

NCT00238914 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00238914 about?

NCT00238914 is a clinical study titled "Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1". The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES: 1. Outpatient treatment wit...

What is the current status of trial NCT00238914?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1999-08. Estimated completion is 2002-07.

What conditions does trial NCT00238914 study?

This clinical trial studies the following conditions: Heroin Dependence.

What interventions are being tested in trial NCT00238914?

The interventions under investigation include: Naltrexone (DRUG), Behavioral Naltrexone Therapy (BNT) (BEHAVIORAL), Compliance Enhancement (CE) (BEHAVIORAL).

Who is sponsoring clinical trial NCT00238914?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00238914 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heroin Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00238914's enrollment target sits among peer trials

12 8th of 8 higher than 1 of 8 other Heroin Dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heroin Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00238914, the US trial registry maintained by the National Library of Medicine. NCT00238914 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.